Shanghai Model Organisms Center Past Earnings Performance
Past criteria checks 0/6
Shanghai Model Organisms Center's earnings have been declining at an average annual rate of -62.2%, while the Life Sciences industry saw earnings growing at 17.2% annually. Revenues have been growing at an average rate of 16% per year.
Key information
-62.2%
Earnings growth rate
-63.3%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 16.0% |
| Return on equity | -1.3% |
| Net Margin | -5.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Shanghai Model Organisms Center makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 363 | -21 | 124 | 79 |
| 30 Jun 24 | 363 | -27 | 123 | 80 |
| 31 Mar 24 | 362 | -19 | 115 | 80 |
| 31 Dec 23 | 367 | -21 | 116 | 80 |
| 30 Sep 23 | 356 | -20 | 112 | 79 |
| 30 Jun 23 | 354 | -13 | 112 | 82 |
| 31 Mar 23 | 318 | -34 | 117 | 74 |
| 31 Dec 22 | 303 | -5 | 101 | 66 |
| 30 Sep 22 | 301 | 22 | 87 | 59 |
| 30 Jun 22 | 283 | 39 | 71 | 51 |
| 31 Mar 22 | 294 | 63 | 61 | 51 |
| 31 Dec 21 | 275 | 61 | 59 | 48 |
| 30 Sep 21 | 259 | 59 | 83 | 68 |
| 30 Jun 21 | 241 | 59 | 50 | 38 |
| 31 Mar 21 | 212 | 50 | 45 | 35 |
| 31 Dec 20 | 196 | 45 | 38 | 34 |
| 31 Dec 19 | 155 | 23 | 37 | 29 |
| 31 Dec 18 | 121 | 15 | 33 | 18 |
| 30 Jun 18 | 100 | 26 | 42 | 0 |
| 31 Mar 18 | 94 | 23 | 39 | 0 |
| 31 Dec 17 | 76 | -16 | 45 | 10 |
| 30 Sep 17 | 82 | 20 | 33 | 0 |
| 30 Jun 17 | 78 | 20 | 29 | 0 |
| 31 Mar 17 | 69 | 17 | 27 | 0 |
| 31 Dec 16 | 61 | 15 | 25 | 0 |
| 31 Dec 15 | 45 | 11 | 19 | 0 |
Quality Earnings: 688265 is currently unprofitable.
Growing Profit Margin: 688265 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688265 is unprofitable, and losses have increased over the past 5 years at a rate of 62.2% per year.
Accelerating Growth: Unable to compare 688265's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 688265 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-14.4%).
Return on Equity
High ROE: 688265 has a negative Return on Equity (-1.28%), as it is currently unprofitable.